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Open Access

Pre- and post-bronchodilator lung function as
predictors of mortality in the Lung Health Study
David M Mannino1,2*, Enrique Diaz-Guzman2 and Sonia Buist3

Abstract
Background: Chronic obstructive pulmonary disease (COPD) is supposed to be classified on the basis of postbronchodilator lung function. Most longitudinal studies of COPD, though, do not have post-bronchodilator lung
function available. We used pre-and post bronchodilator lung function data from the Lung Health Study to
determine whether these measures differ in their ability to predict mortality.
Methods: We limited our analysis to subjects who were of black or white race, on whom we had complete data,
and who participated at either the 1 year or the 5 year follow-up visit. We classified subjects based on their
baseline lung function, according to COPD Classification criteria using both pre- and post-bronchodilator lung
function. We conducted a survival analysis and logistic regression predicting death and controlling for age, sex,
race, treatment group, smoking status, and measures of lung function (either pre- or post-bronchodilator. We
calculated hazard ratios (HR) with 95% confidence intervals (CI) and also calculated area under the curve for the
logistic regression models.
Results: By year 15 of the study, 721 of the original 5,887 study subjects had died. In the year 1 sample survival
models, a higher FEV1 % predicted lower mortality in both the pre-bronchodilator (HR 0.87, 95% CI 0.81, 0.94 per
10% increase) and post-bronchodilator (HR 0.84, 95% CI 0.77, 0.90) models. The area under the curve for the
respective models was 69.2% and 69.4%. Similarly, using categories, when compared to people with “normal” lung
function, subjects with Stage 3 or 4 disease had similar mortality in both the pre- (HR 1.51, 95% CI 0.75, 3.03) and
post-bronchodilator (HR 1.45, 95% CI 0.41, 5.15) models. In the year 5 sample, when a larger proportion of subjects
had Stage 3 or 4 disease (6.4% in the pre-bronchodilator group), mortality was significantly increased in both the
pre- (HR 2.68, 95% CI 1.51, 4.75) and post-bronchodilator (HR 2.46, 95% CI 1.63, 3.73) models.
Conclusions: Both pre- and post-bronchodilator lung function predicted mortality in this analysis with a similar
degree of accuracy. Post-bronchodilator lung function may not be needed in population studies that predict longterm outcomes.
Keywords: COPD, mortality, epidemiology, bronchodilator responsiveness

Background
COPD is a chronic disease of the lungs and is characterized by irreversible airflow limitation, and is currently
the third leading cause of death in the United States
[1-3]. GOLD defines COPD as a preventable and treatable disease with airflow limitation that is usually progressive and associated with an abnormal inflammatory
response of the lung to noxious particles or gases [4].
Both the American Thoracic Society (ATS) and the
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European Respiratory Society (ERS) have, in large part,
adopted this definition [5].
Response to a bronchodilator is thought to be important in COPD diagnosis and guidelines suggest that classification of COPD be made using spirometry performed
after bronchodilator administration [4]. While asthma
generally has more reversibility to a bronchodilator than
COPD, the presence of reversibility does not distinguish
asthma from COPD [6].
According to the 2008 GOLD guidelines “Spirometry
should be performed after the administration of an adequate dose of an inhaled bronchodilator (e.g., 400 μg
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salbutamol) [7] in order to minimize variability. In a
random population study to determine spirometry reference values, post-bronchodilator values differed from
pre-bronchodilator values [8]. Furthermore, postbronchodilator lung function testing in a community
setting has been demonstrated to be an effective method
to identify individuals with COPD [9,10]. However, most
longitudinal studies looking at the effect of impaired
lung function on outcomes such as mortality and hospitalizations have used pre-bronchodilator lung function
[11-14].
The purpose of this study is to determine whether
pre- or post-bronchodilator lung function differentially
predict mortality in cohorts over time. Data from the
Lung Health Study [15] was used in this analysis.
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Study Measures

Predicted values from the Third National Health and
Nutrition Examination Survey (NHANES III) were used
in the analysis [19]. We used age, sex, height and race
to determine the predicted values. The study participants were classified, using the pre- and post-bronchodilator lung function, into five lung function categories
based on a modification of COPD classification criteria:
Normal (no airflow obstruction or restriction), restricted
(FEV1/FVC ≥ 70% and FVC < 80% of predicted), Stage 1
(FEV1/FVC < 70% and FEV1 ≥ 80% predicted), Stage 2
(FEV 1/FVC < 70% and 50% ≤ FEV 1 < 80% predicted),
and Stage 3 or 4 (FEV 1 /FVC < 70% and FEV 1 < 50%
predicted) [4].
Definitions

Methods
The Lung Health Study (LHS) was a randomized multicenter clinical trial that was carried out from October
1986 through April 1994 [15,16]. A detailed description
of the LHS design has been previously published [16].
Briefly, “healthy” current smokers between the ages of 35
and 60 were enrolled if their forced expiratory volume in
one second (FEV1) to forced vital capacity (FVC) was less
than 70% and their FEV1 was between 55% and 90% of
the predicted normal value. Subjects were randomized
into three groups: a control group receiving “usual care”,
a smoking intervention group receiving placebo, and a
smoking intervention group receiving the bronchodilator
ipratroprium. Lung function was measured before and
after two inhalations (200-μg total dose) of isoproteronol
from a metered-dose inhaler.
We used data from the year 1(one year following
baseline) and year 5 (5 years following baseline) visits
and included subjects who had complete data and both
pre- and post-bronchodilator lung function measurements at these visits. The rationale for using these visits
was that the inclusion criteria limited the range of lung
disease severity at baseline to mild and moderate
COPD, whereas a broader range could be seen in subsequent visits. In addition, prior work has demonstrated
that bronchodilator responsiveness was larger in year 1
and subsequent years than it was at baseline [17].
About 75% of the original cohort of 5887 participants
were followed continuously for 10 years beyond the 5year time frame of Lung Health Study I (these subjects
were mostly participants in Lung Health Study III) by
biannual phone contacts (to ascertain vital status, smoking status, morbidity and mortality). Our primary endpoint was all-cause mortality at up to 14.5 years of
follow-up from baseline [18]. The time metric used was
time from the year 1 examination to the time of death
or the end of the study or from the year 5 examination
to the end of the study.

Demographic data included in this analysis were sex,
age, body mass index (BMI), smoking status, race, and
educational status. Age was classified at baseline, the
year 1, and year 5 examinations and was categorized for
use in tables (35-39, 40-49, 50-50, and 60 and older),
and was used as a continuous variable in the survival
analyses. BMI was categorized at baseline and was categorized into 3 categories (< 25, 25-29, and > = 30 kg/
m2), and was used as a continuous variable in the survival analyses. All subjects were smokers at baseline, so
smoking status was classified based on their second
through fifth follow-up visits as current smokers for
those who never stopped smoking, former smokers for
those who successfully quit, and intermittent smokers
for those whose status varied [20]. Education status was
stratified into three levels (< 12 years, 12 years, and > 12
years). Race was classified as White or Black, with people of other races excluded. The original design of the
study was incorporated by stratifying the subjects by
randomization group: Intervention with ipratroprium,
Intervention with placebo, and Control.
Statistical Analysis

Data analysis was completed using statistical software
(Statistical Analysis Software, version 9.2; SAS Institute;
Cary, NC and SUDAAN version 10.1; RTI, Research
Triangle Park, NC). Our primary outcome of interest in
the survival models was mortality, and the main predictor of interest in our analysis was COPD severity
defined by stage of lung function, both pre- and postbronchodilator, and a separate analysis using FEV1 as a
percent of predicted, both pre- and post-bronchodilator.
We calculated the deaths per 1,000 person years of follow-up for our key covariates. Cox proportional hazard
regression models were developed using the SUDAAN
procedure SURVIVAL to account for differential follow
up in cohort participants. Time of follow up was used
as the underlying time metric. Censoring occurred at
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the date of death certificate or date the participant was
last known to be alive. Plots of the log-log survival
curves for each covariate were produced to evaluate the
proportional hazards assumptions. Age, sex, race, smoking status, education level, body mass index and randomization cohort were included in the adjusted models.

Results
There were a total of 5,887 participants in the Lung
Health Study, of whom 721 died by the end of the follow-up period of up to 15 years. The major causes of
death at follow-up were lung cancer and cardiovascular
disease with comparatively fewer deaths due to nonmalignant respiratory disease. At baseline, the mean age
of the cohort was 48.5 years and the mean FEV1 was
74.7%. Of these, we had complete data on 5,307 who
participated in the examination at year 1 (there were 13
deaths before the year 1 visit). Among the 5,307 on
whom we had complete data at year 1, we had 65,472
person years of follow-up, with a median and maximum
follow-up time of 12.8 and 14.0 years, and 628 deaths
(Table 1). Among the 5,320 on whom we had complete
data at year 5 (there were 149 deaths prior to the year 5
visit), we had 45,808 person years of follow-up, with a
median and maximum follow-up time of 8.8 and 10.0
years, and 500 deaths (Table 2).
Table 1 provides additional detail on the covariates of
the cohort at year 1, including the total follow-up time
and the mortality rate per 1,000 person-years of followup. As would be expected, age was the strongest predictor of mortality. Similar data for the Year 5 cohort is
displayed in Table 2.
Changes in the COPD classification stages between
pre- and post-bronchodilator lung function measurements for the year 1 and the year cohort is shown in
Table 3. At year 1, 3,804 of 5,307 (71.7%) remained in
the same category for both pre- and post-bronchodilator
FEV1and at year 5, 4,079 of 5,320 (76.7%) remained in
the same category for both pre- and post-bronchodilator
FEV 1 . The mean FEV 1 , as a percentage of predicted,
increased from 74.1% (Standard deviation [SD] 10.3%)
to78.1% (SD 10.0%) at year 1 and from 70.3% (SD
12.5%) to 74.3% (SD 12.1%) at year 5.
The Cox proportional hazards models for the year 1
cohort are shown in Table 4. Age, sex, education level,
race, and smoking status were significant predictors of
mortality, but in these models COPD classification stage
reached statistical significance in only stage 2 of the
post-bronchodilator model. The area under the curve,
from the PROC logistic model, was 69.2% for the preand 69.6% for the post- bronchodilator model. In parallel models that used pre- and post-bronchodilator FEV1,
as a percentage of predicted, a higher FEV1 % predicted
lower mortality in both the pre- (HR 0.87, 95% CI 0.81,
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0.94 per 10% increase) and post-bronchodilator (HR
0.84, 95% CI 0.77, 0.90) models. The area under the
curve for the respective models was 69.2% and 69.4%.
Similar models for the year 5 follow-up data are
shown in Table 5. The main difference seen between
the year 1 and year 5 models is that the latter now show
an increased risk of Stage 3 or 4 COPD on mortality in
both the pre- (HR 2.68, 95% CI 1.51, 4.75) and postbronchodilator (HR 2.46, 95% CI 1.63, 3.73) models.
The area under the curve was 69.0% for the pre- and
69.5% for the post-bronchodilator models. Similar models using FEV1 showed that a higher FEV1 % predicted
lower mortality in both the pre-bronchodilator (HR
0.84, 95% CI 0.75, 0.87 per 10% increase) and postbronchodilator (HR 0.78, 95% CI 0.73, 0.90) models.
The area under the curve for the respective models was
69.4% and 69.8%.

Discussion
This analysis examined data from the Lung Health
Study to determine whether post-bronchodilator lung
function predicts mortality. Overall, we found that the
pre- and post-bronchodilator measures of lung function,
whether used categorically (as stages of COPD) or continuously (as FEV 1 % predicted) predicted mortality
similarly. This finding suggests that post-bronchodilator
lung function data may not be needed for studies that
look at long term outcomes in COPD.
Most guidelines defining COPD say that spirometry
should be performed after the administration of an adequate dose of an inhaled bronchodilator in order to
minimize variability [4,21]. These same guidelines, however, state that “neither bronchodilator nor oral glucocorticosteroid reversibility testing predicts disease
progression, whether judged by decline in FEV1, deterioration of health status, or frequency of exacerbations
in patients with a clinical diagnosis of COPD and abnormal spirometry. Small changes in FEV1 (e.g., < 400 ml)
after administration of a bronchodilator do not reliably
predict the patient’s response to treatment" [4]. Others
have suggested that one cannot use prebronchodilator
lung function to define COPD, the reason being that
airflow limitation can be variable and that this component can be easily reverse with a bronchodilator [22].
Other research, though, has suggested that bronchodilator responsiveness is highly variable and that “over half
the patients initially classified as reversible by the ATS/
GOLD definition would be reclassified had they
attended on another occasion” [23].
In population-based studies, one would expect that
post-bronchodilator lung function measurement would
reduce the prevalence of COPD. For example, in the
PLATINO study, bronchodilator testing reduced the
overall prevalence of FEV1/FVC% < 0.70 from 21.7% to
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Table 1 Characteristics of Analyzed Population at Year 1
(n = 5,307) with 628 deaths at up to 15 years of followup
N

%

Person-Years of
Follow-up

Table 2 Characteristics of Analyzed Population at Year 5
(n = 5,320) with 500 deaths at up to 10 years of followup

Deaths per 1,000
Person Years

Sex

N

%

Person-Years
of Follow-up

Deaths per 1,000
Person Years

Sex
Female

1993 37.6

24,764

8.3

Female

1,992 37.4

17,221

9.4

Male

3314 62.4

40,708

10.4

Male

3,328 62.6

28,587

11.8

9.8

6,610

3.8

35-39

214

9.3

40-49

2099 39.6

26,350

5.5

40-49

1,708 32.1

14,995

4.7

50-59
60+

2494 47.0
192 3.6

30,267
2,245

13.7
18.7

50-59
60+

2,436 45.8
1,151 21.6

20,954
9,644

11.4
19.7

Age Group, Years
35-39

Body Mass Index,
kg/m2
< 25

Age Group, years
522

25

0.5

Body Mass Index, kg/
m2
2528 47.6

31,168

9.5

< 25

2,536 47.7

21,849

10.7

25- 30

2082 39.2

25,791

9.1

25- 30

2,098 39.4

18,075

10.6

> = 30

697 13.1

8,513

11.5

> = 30

686 12.9

5,884

12.7

Education, Years
< 12

Education (years)
632 11.9

7,720

13.0

< 12

639 12.0

5,496

14.0

12

1592 30.0

19,629

10.0

12

1,595 30.0

13,735

11.5

> 12

3083 58.1

38,123

8.7

> 12

3,086 58.0

26,577

10.0

5,136 96.5

Race

Race
White
Black

5108 96.3

63,117

9.2

White

3.7

2,355

20.8

Non-White

1439 27.1

17,966

7.0

Former

628 11.8

7,752

9.5

Intermittent

3240 61.1

39,754

10.8

Current

199

Smoking Status
Former
Intermittent
Current

44,226

10.6

3.5

1,582

19.6

1,386 26.1

12,063

7.5

627 11.8

5,403

10.2

3,307 62.2

28,342

12.5

15,470

9.6

15,271

10.5

15,067

12.7

184

Smoking Status

Randomization
Group

Randomization Group
Intervention,
1,791 33.7
Ipratroprium
Intervention,
1,770 33.3
Placebo
Control
1,759 33.1

Intervention,
Ipratroprium

1793 33.8

22,141

8.9

Intervention,
Placebo

1785 33.6

22,108

9.0

1729 32.6

21,223

11.0

6.4

2,831

21.5

Stage 3 or 4
Stage 2

67 1.3
3432 64.7

799
42,208

15.0
10.7

Stage 2

3,587 67.4

30,875

11.3

Stage 1

995 18.7

8,674

7.3

Stage 1

1354 25.5

16,852

7.3

Restricted

Control
Stage (prebronchodilator)*

Restricted
Normal

Stage 3 or 4

341

92

1.7

768

15.6

305

5.7

2,659

5.6

183

69

1.3

840

9.5

Normal

385

7.3

4,773

6.7

Stage (postbronchodilator)*
3.4

1,475

29.8

19

0.4

224

13.4

Stage 2

3,048 57.3

26,237

12.0

Stage 1
Restricted

1,242 23.3
126 2.4

10,775
1,059

7.2
13.2

721 13.6

6,262

7.8

Stage (postbronchodilator)*
Stage 3 or 4

Stage (prebronchodilator)*

Stage 3 or 4

Stage 2

2540 47.9

31,126

12.1

Stage 1

1565 29.5

19,386

7.8

Restricted
Normal

125 2.4
1058 19.9

1,487
13,249

12.1
5.8

Normal

*Modified chronic obstructive pulmonary disease stage, as defined in methods

*Modified chronic obstructive pulmonary disease stage, as defined in methods

14% [24]. In our analysis the prevalence of severe COPD
was lower in the post- compared to the pre-bronchodilator lung function in both the year 1 (0.4% vs. 1.3%)

and the year 5 (3.4% vs. 6.4%) cohorts. The finding of a
lower prevalence, however, does not necessarily mean
that this is the correct prevalence.
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Table 3 Comparison of pre- and post-bronchodilator classifications from Year 1 and Year 5 visits
Year 1

Post-Bronchodilator

Pre-Bronchodilator

Stage 3 or 4*

Stage 2

Stage 1

Restricted

Normal

Stage 3 or 4*

17

50

0

0

0

Total

Stage 2

1

2442

578

76

335

3432

Stage 1

0

28

959

0

367

1354

Restricted

1

10

0

44

14

69

Normal

0

10

28

5

342

385

Total

19

2540

1565

125

1058

5307

Total

67

Year 5
Post-Bronchodilator
Pre-Bronchodilator

Stage 3 or 4*

Stage 2

Stage 1

Restricted

Normal

Stage 3 or 4*

172

168

0

1

0

Stage 2

10

2823

482

67

205

3587
995

341

Stage 1

0

27

748

0

220

Restricted

1

18

1

56

16

92

Normal

0

12

11

2

280

305

Total

183

3048

1242

126

721

5320

The rows represent the pre-bronchodilator values and the columns represent the post-bronchodilator values (i.e. at year one 67/5307 were stage 3 or 4 pre- and
19/5307 were stage 3 or 4 post-bronchodilator). Year 1 Post-Bronchodilator
*Modified chronic obstructive pulmonary disease stage, as defined in methods

Others have looked at this problem in different ways.
For example, Hansen et al studied 985 patients with
COPD and found that the response to a bronchodilator
was a positive prognostic factor along with FEV1 at baseline. However, if baseline FEV1 was substituted with postbronchodilator FEV 1 , the bronchodilator reversibility
became nonsignificant [25]. Compared to our population,
that population had much lower lung function (mean
FEV1 38.5% of predicted compared to our mean FEV1 of
74.7%) and was much older (mean age 61.8 years at baseline compared to our mean age of 48.5 years). Still, the
predictive value for FEV1 in their study was similar in the
pre- (relative risk [RR] 0.60, 95% CI 0.54, 0.81) and postbronchodilator (RR 0.62, 95% CI 0.56, 0.69) models.
Burrows acknowledged the complexity of the relation
between bronchodilator responsiveness and outcomes in
obstructive lung disease [26]. He noted that different
studies had varying results [27,28] and suggested that
several factors, such as how baseline lung function is
determined, how responsiveness is measured, and the
prevalence of “asthma” in the studied population, may
be important determinants of outcomes. His conclusion
that mortality is “related to age and to a low initial postbronchodilator FEV 1 “ provides, in part, the historic
rationale for using post-bronchodilator lung function to
define COPD.
This study has limitations that are important to its
interpretation. The most important was that it was not
a true “population-based” study but was a clinical
intervention trial that targeted early COPD. Study participants had to be current smokers at entry with lung
function that was mildly abnormal, and subjects who

regularly used bronchodilators were excluded.
Although asthma history was not a specific exclusion
criterion, excluding people with regular bronchodilator
use had the net effect of eliminating subjects with
clinically significant asthma from the population. Thus,
these findings may not necessarily apply to a population that includes never smokers or where a large proportion of the population has asthma that is
symptomatic. Also, a more inclusive population of
smokers where reversibility is more common may have
yielded different results. This limitation is decreased by
our study design that looked at data from the year 1
and year 5 follow-up, at which point some subjects
had stopped smoking and many developed symptoms
consistent with asthma or COPD. In addition, one
would not expect the post-bronchodilator FEV 1 of
never smokers (in the absence of asthma) to differ significantly from the pre-bronchodilator value. Finally,
the dose of bronchodilator used in this study (two
inhalations, 200-μg total dose, of isoproterenol) is less
than what has been used in other clinical trials, some
of which have used 400 μg of isoproterenol and 400 μg
of albuterol [29]. Thus, it is unknown whether the
findings would be similar if a “maximal bronchodilitation” protocol was used.
Another limitation was the absence of other important
measures of COPD, such as an impaired exercise testing, impaired diffusion capacity or abnormal imaging.
Recent work [30-32] in COPD has highlighted that measures other than lung function are important predictors
of impaired function and poor outcomes. Lung function
remains, however, the primary means of diagnosing and
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Table 4 Results from Cox Proportional hazards survival
models on year 1 sample- Mortality follow-up of up to
15 years
Hazards
Ratio

95% Confidence
Interval

Table 5 Results from Year 5 sample, mortality follow-up
of up to 10 years
Hazards
Ratio
Sex

Sex
Male
Female

1.34

Male

1.36

(1.12, 1.59)

Female

1.00
1.09
1.01

1.00

95% Confidence
Interval

Age

1.09

(1.07, 1.10)

Age
Body Mass Index

Body Mass Index

1.00

(0.98, 1.03)

Education

< 12 Years
12 Years

1.29
1.08

(1.03, 1.61)
(0.90, 1.29)

> 12 Years

1.00

White

1.00

Black

2.13

(1.57, 2.88)

Former Smoker

0.64

(0.52, 0.79)

Intermittent Smoker
Current Smoker

0.89
1.00

(0.69, 1.15)

Intervention,
Ipratroprium

0.92

(0.76, 1.12)

Intervention, Placebo

0.89

(0.74, 1.09)

Control

1.00

Education

(1.12, 1.64)
(1.07, 1.10)
(0.98, 1.03)

< 12 Years

1.24

(0.96, 1.59)

12 Years

1.10

(0.90, 1.34)

> 12 Years

1.00

Race

Race

Smoking Status

White

1.00

Black
Smoking Status

1.77

(1.22, 2.56)

Former Smoker

0.63

(0.50, 0.80)

Intermittent Smoker

0.85

(0.64, 1.13)

Current Smoker

1.00

Randomization Group

Randomization Group

Intervention,
Ipratroprium

0.86

(0.69, 1.07)

Intervention, Placebo

0.91

(0.74, 1.13)

Control

1.00

Stage (Pre-bronchodilator)*
Stage 3 or 4

Stage (Pre-bronchodilator)*

2.68

(1.51, 4.75)

Stage 3 or 4

1.51

(0.75, 3.03)

Stage 2

1.60

(0.94, 2.69)

Stage 2

1.36

(0.95, 1.95)

Stage 1

1.12

(0.63, 1.98)

Stage 1
Restricted

0.97
1.12

(0.65, 1.44)
(0.51, 2.48)

Restricted

2.25

(1.04, 4.86)

Normal

1.00

Normal

1.00

Stage (Post-bronchodilator)*

Stage (Post-bronchodilator)*

Stage 3 or 4

2.46

(1.63, 3.73)

(1.20, 1.98)

Stage 2
Stage 1

1.11
0.74

(0.82, 1.51)
(0.52, 1.06)

1.06

(0.80, 1.40)

Restricted

1.36

(0.74, 2.47)

1.63

(0.96, 2.75)

Normal

1.00

Stage 3 or 4

1.45

(0.41, 5.15)

Stage 2

1.54

Stage 1
Restricted
Normal

1.00

*Modified chronic obstructive pulmonary disease stage, as defined in methods

Results for post-bronchodilator lung function measurement is displayed
without showing results for the other covariates.
*Modified chronic obstructive pulmonary disease stage, as defined in methods

classifying COPD at the present time and this is unlikely
to change in the foreseeable future.

Conclusion
We found that is this cohort both pre- and post-bronchodilator lung function predicted mortality with similar
accuracy. This validates the approach taken in a number
of long-term studies where only prebronchodilator lung
function is available, although studies that include similar data in never smokers and subjects with asthma are
needed.
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